Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix H. LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 65.50p 64.00p 67.00p 65.50p 65.50p 65.50p 13,782.00 07:46:34
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -1.4 1.8 37.4 51.20

Optibiotix H. (OPTI) Latest News

More Optibiotix H. News
Optibiotix H. Takeover Rumours

Optibiotix H. (OPTI) Share Charts

1 Year Optibiotix H. Chart

1 Year Optibiotix H. Chart

1 Month Optibiotix H. Chart

1 Month Optibiotix H. Chart

Intraday Optibiotix H. Chart

Intraday Optibiotix H. Chart

Optibiotix H. (OPTI) Discussions and Chat

Optibiotix H. Forums and Chat

Date Time Title Posts
09/12/201611:30OptiBiotix - Better Science, Better Health. Better buy some!17,796.00
07/12/201615:12OptiBiotix - The uncensored thread 745.00
23/8/201607:35Outlook2.00
18/8/201611:36Optibiotix (OPTI) wins investors as platforms expand9.00
07/4/201607:23Tasty RNS-

Add a New Thread

Optibiotix H. (OPTI) Top Chat Posts

DateSubject
09/12/2016
08:20
Optibiotix H. Daily Update: Optibiotix H. is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix H. was 65.50p.
Optibiotix H. has a 4 week average price of 65.50p and a 12 week average price of 67.65p.
The 1 year high share price is 94p while the 1 year low share price is currently 60.25p.
There are currently 78,164,259 shares in issue and the average daily traded volume is 96,495 shares. The market capitalisation of Optibiotix H. is £51,197,589.65.
01/11/2016
10:57
mouse20: Stephen O'Hara, founder and chief executive of OptiBiotix (OPTI), is ambitious. In a recent scientific and commercial update, he made reference to an $82m (£67m) acquisition of a single microbial strain in a deal between two fellow microbiome companies. According to Mr O'Hara, OptiBiotix (which owns many patented microbial strains) is of a similar ilk. But the group's market capitalisation of £51.6m doesn't, at present, reflect that. It is nonetheless impressive considering just two years ago when OptiBiotix joined Aim its market capitalisation was £6m. The group's share price ticked up gradually throughout 2015 amid the many scientific and commercial updates and rose to its all-time high in November 2015 after the group signed an agreement with Italian health foods company CSL to create novel, low-calorie sugars using Opti's OptiBiotic technology platform. http://www.investorschronicle.co.uk/2016/11/01/comment/chronic-investor-blog/chart-has-optibiotix-got-eyes-bigger-than-its-stomach-UJ3vM1uoCPkKw4bVfrPSxN/article.html
24/10/2016
17:45
riskybusiness1: To those who are starting to worry because of lack of news and share price drift:- The CEO has a holding far greater than any of ours combined. He'll act in the best interest of shareholders in every decision made as he clearly has more than us- the CEO sold his last company to a global corporate (3m). 3m did not sell the product anywhere near the numbers agreed in an earn out agreement. 3m priorities changed during the financial crisis - soh took them to court and I think he won.Clearly because of this he definitely won't be sold short even if it means snubbing the big guns. AB-biotic have a deal with DUPONT...at first glance this is great however just look at the sales. DuPont have screwed ab-life somewhat. What choice have they got now? That's exactly the type of deal we need to avoid. - opti at a current cash burn rate circa 80-100k a month with over £3m currently in the bank gives us a timeframe of nearly 3 years to get a half decent revenue bearing deal. This gives us the ability to find the right deal. Go figure is currently selling and cutting these small overheads as we speak (marginally but growing fast).- the most potentially lucrative platform: optibiotics recently announced its success in increasing the growth rate of specific strains e.g it's cholesterol product. This allows us to improve our already brilliant efficacy taken from our first trials. Potentially to statin reducing standards as we had a 7% reduction across the board with 36% reduction within the group with higher cholesterol levels. All with a minuscule dosage of 0.1g. The optibiotic technology platform used to enhance its cholesterol strain recently successfully holds a deal with dsm to create products that have a direct agreement that ends with us receiving royalties.Another part of this platform, the sweet healthy sugars that have no calories has recently been announced a success in its sweetness. This alone is a value enhancing step that the market payed no attention to due to its focus on the cholesterol deal.This means we have the means to target specific microbes increasing their growth rate giving a specific targeted health benefit. This is revolutionary to the whole industry. It also means we now have the ability to create a sweet sugar that can reduce your cholesterol. Put a value on that? If this is replicated with a diabetes strain targeted through our validated opti screen and then enhanced through our optibiotics platform then we are laughing. This would give us sweet tasting sugar that helps diabetic sufferers.If you really are worried with developments think why you invested in the first place. Then realise how far this company has come in 2 years and how these concepts are all turning in to realities. Let alone entering skin space due to the successes. The deals will come, just look at the technology compared to what's currently in the market. I've said before it's like moving from a road map to the sat nav. They're all going to do it it's just when and will you be in opti when it happens. The story has never been better here. Don't get blinded by a share price that has not reflected developments.
20/10/2016
06:50
michaelmouse: http://uk.advfn.com/stock-market/london/optibiotix-h-OPTI/share-news/OptiBiotix-Health-PLC-Increased-investment-in-Skin/72706610 "Under the terms of the agreement, OptiBiotix has increased its investment into SkinBiotix, using a Convertible Loan Agreement, with an investment of GBP400k which will provide funding to complete the development and human studies for the first product application, in addition to funding activities to support an Initial Public Offering ("IPO")." You all need to read this bit more carefully. The funding activities in the proposed IPO are expected to provide the bulk of the monies for the development work. However, as I said in my previous post, this appears to be in some doubt. If the IPO doesn't go ahead then expect substantially larger dilution at conversion prices well below the current share price. If the IPO doesn't go ahead then the share price discount on conversion will be massive. Less than 40p ish or more. Why? Think about the disappointment, and their clear intention for far more funding rounds. Remember SkinBiotix is not the only proposed "spin-off" where they will need to raise huge amounts of cash going forward. Cash raised in this round alone (I'd guess) will be well over a £1m and that's just for the development work of a single product. Bargepole territory.
11/10/2016
10:25
parob: http://www.directorstalk.com/qa-stephen-ohara-chief-executive-officer-optibiotix-health-plc-lonopti-3/ Q&A with Stephen O'Hara Chief Executive Officer at Optibiotix Health PLC (LON:OPTI)Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O'Hara caught up with DirectorsTalk to discuss the new appointment of Martin Hunt as Chairman at SkinBiotics, how this fits into their strategy and what it means for shareholders Q1: Now Stephen, can you tell me more about the appointment of your new Chairman at the SkinBiotix division of Optibiotix Health?A1: Yes, sure. In July of this year Optibiotix announced a strategy to demerge and list as separate divisions and the appointment of the Chairman that we announced in the RNS is the start of this process. It's the process of demerging SkinBiotix and we think this is an important step in the development of SkinBiotics as we build a dedicated team, with dedicated leadership who have the expertise in the biotherapeutic space. I think investors have to realise that it's a very different space to the other Optibiotix divisions and requires specialised industry knowledge in cosmetics, medical devices and in pharmaceuticals and Martin's appointment is to start a process of building a dedicated team and a dedicated leadership with the industry knowledge and expertise to fully exploit the opportunities that we see in the microbiome space particularly in the skin microbiome space. Q2: So what could this mean for Optibiotix's investor and how will it fit into your overall strategy?A2: Well our strategy is to build value for shareholders as part of that process, we're looking to build each division to a point where we can demerge then list it separately, if you look at SkinBiotix and look at the area that it works in, we don't believe that the market really recognises the value within SkinBiotix, let me give you a couple of examples. The first example is the size of the market opportunity in skin so these market opportunities include cosmetic skin care, a market of $121 billion, healthcare-acquired infections, a market of $82 billion, dermatology, and $10 billion on wound care. I guess the other aspect is that if you look at the other ways in terms of value in a company over the market opportunities that it's targeting is the value of comparison so SkinBiotix is in the biotherapeutic space and if you could comparate a company such a 4D Pharma their valuations tend to be in the hundreds of millions rather than the tens of millions and we think that with SkinBiotix the true value of the division within Optibiotix is not being fully realised. By taking it out of Optibiotix and putting it into a separate company, which is demerge Optibiotix and then list it separately will best realise value for shareholders and there's other examples of this that have set a precedent for this type of approach and they include Racal who spun off Vodafone and Chubb and more recently Paypal from Ebay. What it means in terms of shareholders is typically they retain their position in Optibiotix but they also gain a proportional position in the new listed company so from a shareholder point of view it's a way of greatly increasing the value of their shareholding. Q3: With that in mind then, when do you think we can expect any listing to happen?A3: We can't give the exact details of when the listing will happen but this is part of the process of looking to list SkinBiotix separately, timing will be market sensitive and we will announce an RNS on that nearer the time. We look at market conditions over the forthcoming months, we look at putting the team in place and getting the right people who we feel can lead a team and who have the expertise to fully exploit the opportunity, once we have those in place we will produce an RNS, we will signal our intent then in terms of a listing. We see this as not a longer term opportunity, we see this, dependant on market conditions, as a short to medium term opportunity and we're pressing ahead on that as I indicated in the earlier question and the first part of that process was appointing a Chairman. So we're really excited by the opportunity and we think it's a great way to build shareholder value, we think if we get it right and we take it to the market then very much like as we did with OptiBiotix we were able to get a great increase in share price and value over a short period of time. We think that SkinBiotix opportunity is very similar; big markets, big opportunities and as I said earlier comparator companies with high market valuations, I think it's a great opportunity here for investors in Optibiotix Health.
09/10/2016
13:03
michaelmouse: post 585 - "Anyway let's see what develops, but bargepole territory for me with every extra bit of PR they produce to try and pump up the price." Oh dear!! Same old, same old. Loss making company tries diversionary tactic i.e. "spin-off" story. Share price has lost 40% of it's value in the past year. A desperate PR attempt is made over the weekend to try and pump up the price next week and halt a total collapse. Yawn. I hope it works for holders because that "rolling top" on the chart is a classic. If the share price doesn't rise on Monday (substantially) then 40p here we come. They need a strong share price to get a spin-off IPO away hence the tipsters trying to get the PIs all worked up over the weekend. The facts remain. They are years away from meaningful revenues and profitability. They need shed loads of more cash. Hence the attempt at a "spin-off". Nervous day for holders on Monday. Share price needs to "take off" on strategic pumping campaign. Follow the Nanoco story. Even when deals are struck, the licensing payments are often laughable. http://uk.advfn.com/stock-market/london/nanoco-NANO/share-news/Nanoco-Group-PLC-Update-re-Unaudited-Revenues/72617298 "The upfront licence fees associated with the agreements are to be recognised over the period of Nanoco's contractual support. It is expected that GBP0.5 million will be released to revenue in the year ending 31 July 2017 and GBP0.7 million will be released over the following six years ending 31 July 2023."
11/9/2016
15:59
riskybusiness1: Within a a few years of listing Opti from concept grew by over 1000%.....My idea of the de merger is that Opti will raise maybe £4m and say for example skinbiotix is also worth £4m. The new company is now worth £8million. Taking this as an example opti currently owns 100% of £4m skinbiotix (51% if u take Manchester uni into consideration - call it 100% to save confusion). My idea is that following the listing Opti will then own 50% of a company now worth £8m. Kind of the same concept of reversing in to a shell. We all know how that went with Opti in a very short space of time. Skinbiotix is the division more geared towards the pharma market. As we all know these companies bring ridiculous valuations. All Opti holders at the time will be given a percentage in this new company equivalent to current holdings within Opti - those in around the 8-10p level of Opti should recognise this as another huge opportunity to make a considerate amount of money. Also as Opti will retain say that 50% of the new £8m skinbiotix - as this company grows Opti share price will increase with it.Seeing as Opti bought 51% of the ip for 250,000£, if you take my example above Opti have increased the skin ip immediately from £250,000 into £2m. This is how you start to realise the value. If I was on Opti board I'd be trying to negotiate a further % of skin ip from Manchester.
11/9/2016
11:20
parob: Some interesting chatter this weekend over on the iii board - thought you guys might be interested. One poster called 'whenimrich com' wrote:"Nice to see the shareprice rise on the back of a cleared stock overhang, as reported by TW on share price He also mentions the impending demerger and how the shares will be re - rated for sure when it is announced to 100p + in maybe a couple of weeks. I understand that holders will get a similar percentage of shares in the new company as they hold in Opti which is understandable, but what I dont understand is what will happen to the share price of Opti after demerger? - if the new company becomes seperated from Opti then the price of Opti should surely fall to allow for this?Thinking of it basically - if you have a company worth 100% and divide it into 5 pieces (for example) then the original company is then worth 20% Can anyone explain how this will work?"In response 'Novy kluk' wrote:"Hi whenimrich com,I will try and answer your question. I think the way such a process would work is the following;# The company will NOT BE GIVING AWAY the shares in the demerged entities, they will be selling them to the market.# Recall SOH's comment in an RNS some months back, that the BOD believes the current value the market puts on the company (e.g. currently equivalent to about 75p per share) is less than the sum of the individual entities, right!# So when the individual entities are floated, the BOD will decide (no doubt with the "help" of exorbitantly paid advisors), at what price they want to "sell the demerged company(s)" to the market.# At this point I am NOT trying to predict what that/those prices might be! I am only using figures now for purposes of explanation!# Also recognise (as I'm sure you do) that the parent company Optibiotix Holdings, is very unlikely to divest more than 49% of the shares in each entity!# So IMHO they are likely to establish a price for each entity - say (FOR EXAMPLE ONLY) 40p per share for Skin Biotix.# Then when they "float", existing shareholders will be allocated "a quantity" of these 40p shares in "some proportion" to their holding. # Parent Optibiotix Holding company will retain 51% of these shares - if the float is successful - valued at 40p per share - thus significantly increasing the value of the company!# And the remaining shares will be sold to the market in an "open offer".# If for "Skin Biotix" this is done on NASDAQ as well as AIM, then there could well be a "feeding-frenzy" for these shares, and the price could well increase significantly - this would further increase the value of the Parent Holding company (who hold 51%). And of course increase the values of each existing shareholders holding.# Continuing this process, if say 5 entities were demeged (of course they might be at varying prices depending on their perceived potentials), and assuming the "floats" were managed properly and were successful, then the Parent company, "Optibiotix Holdings" will hold 51% in each of the entities - then most likely to at prices which additively will be significantly higher than today's 75p!Whilst not an expert, I'm sure what I've outlined is quite close to the process that would happen. I hope this helps!GLTA NKI should have added that the proceeds of the sale of shares in the "open offer", will also of course accrue to the Parent "Optibiotox Holdings"!NK"
24/8/2016
13:45
lodger: Say OPTI create a new company and give holders shares in proportion to their current holding, would SB companies automatically give you new bets with the equivalent number of shares, or would they say you don't actually hold the shares so you don't have the rights so if the OPTI share price halves then tough (even though actual holders might not be any worse off because they hold new company shares to roughly balance the drop). It depends on whether the SB companies treat the shares they've had to buy to offset your bet, but I've no idea about rights etc...
24/8/2016
13:27
elrico: Lodger- No change, you SB price will mirror the OPTI price as normal. If OPTI tank, so does you SB if it's long. Any company split is likely to be next year, possibly around ISA season, who knows. Market conditions will dictate the timing. I don't agree with TT's thoughts on the share price retracing by the value of the shares issued, but then this will depend on the issued share capital and how it is distributed. There is likely to be an incentive for holders to hold as many shares in OPTI to maximise returns. There are so many ways OPTI can do this. In any event, it's all speculation right now.
12/8/2016
13:27
riskybusiness1: 2016 has performed better than planned I would say other than share price performance... Thought we'd be looking at 2017 to see products on the shelves. Though the share price has remained stagnate (not helped with consistent seller around 80+ mark which has halted any upward momentum) the progress has been immense in terms of positioning for the future. You could have gone elsewhere made a quick buck however when this lifts off big money will be made. I don't think people realise our value is based upon our ip, we are selling TECHNOLOGY rather than actual products. This ip is then translated in to gaining a minuscule % of these massive markets that are growing at more than 10% per year. Opti has been snapping up ip this year with some being independently valued at £250m - purchased for 250k. Think that actually made the share price go down if I remember?? Reinforces soh reasons for splitting the company up into separate divisions and listing them separately. Many here just looking at the share price rather than what's being created.Obviously we all make money when share price goes up... disappointing little progress on that front this year however I couldn't be happier with the developments. Impatience to go elsewhere will be very costly for many in the long run is my honest opinion. These deals have come out of the blue so far. So many fronts to hear from
Optibiotix H. share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20161209 11:42:20